New Research Links GLP-1 Medications to Reduced Breast Cancer Risk
WHO:
ABC News - More than 111,000 women ages 45 to 80 participated in the study.
WHAT:
ABC News - A new study of more than 111,000 women ages 45 to 80 found those on GLP-1 medications had a reduced risk of developing breast cancer by about 30%.
Science Daily - A study of more than 600,000 U.S. veterans found that GLP-1 drugs, such as semaglutide, may reduce the likelihood of developing substance use disorders involving alcohol, nicotine, cannabis, cocaine, opioids, and other drugs.
Science Daily - The same study indicated that individuals already struggling with addiction experienced fewer overdoses, hospitalizations, emergency visits, and drug-related deaths while taking GLP-1 medications.
ABC News - The study found that women on GLP-1 medications had a reduced risk of developing breast cancer by about 30%.
The Washington Post - GLP-1 drugs have transformed the treatment of diabetes and impacted the science and culture of weight loss.
WHERE:
ABC News - The study involved women from various locations, though specific locations were not detailed in the article.
WHEN:
The Washington Post - The growing body of research regarding GLP-1 drugs and their potential cancer protection is ongoing.
WHY:
The Washington Post - Research is raising the possibility that GLP-1 medications may help protect against cancer.
HOW:
The Washington Post - The mechanisms by which GLP-1 drugs may protect against cancer are being explored through a growing body of research.
(UPDATED June 4, 2026 01:51 UTC)
A new study involving over 111,000 women aged 45 to 80 has revealed that those taking GLP-1 medications experienced a significant reduction in their risk of developing breast cancer, with the risk lowered by approximately 30%. This finding highlights the potential benefits of GLP-1 drugs beyond their primary use. The research underscores the importance of ongoing studies to better understand how these medications can impact women's health.
--
(UPDATED June 3, 2026 23:31 UTC)
A new study involving over 600,000 U.S. veterans has found that GLP-1 drugs, like semaglutide, could lower the chances of developing substance use disorders related to alcohol, nicotine, cannabis, cocaine, opioids, and other drugs. Additionally, the research revealed that those already battling addiction saw a decrease in overdoses, hospitalizations, emergency visits, and drug-related deaths while using GLP-1 medications. This promising data highlights the potential benefits of these drugs in addressing substance use issues among veterans.
--
(UPDATED June 3, 2026 21:58 UTC)
A recent study involving over 111,000 women aged 45 to 80 found that those taking GLP-1 medications had about a 30% reduced risk of developing breast cancer. This research highlights the ongoing exploration of how GLP-1 drugs, which have already transformed diabetes treatment and influenced weight loss culture, may also offer cancer protection. As scientists continue to investigate the mechanisms behind these potential benefits, the conversation around GLP-1 medications is becoming increasingly significant.